Cas no 14167-12-5 (Iron,[[2,2'-[1,2-ethanediylbis[(nitrilo-kN)methylidyne]]bis[phenolato-kO]](2-)]-)
Iron,[[2,2'-[1,2-ethanediylbis[(nitrilo-kN)methylidyne]]bis[phenolato-kO]](2-)]- Chemical and Physical Properties
Names and Identifiers
-
- Iron,[[2,2'-[1,2-ethanediylbis[(nitrilo-kN)methylidyne]]bis[phenolato-kO]](2-)]-
- N,N’-Bis(salicylidene)ethylenediamine Iron(II)
- N,N'-DISALICYLAL-ETHYLENEDIAMINE IRON(II)
- N,N'-Bis(salicylidene)ethylenediamine Iron(II)
- N,N'-Disalicylalethylenediamine Iron(II)
- N,N'-Ethylenebis(salicylideneiminato)iron(II)
- disalicylalethylenediamineiron
- N,N'-Disalicylalethylenediamine Iron(II) N,N'-Ethylenebis(salicylideneiminato)iron(II)
- N,N'-ETHYLENEBIS(SALICYLIDENEIMINATO) IRON(II)
- 2-[2-[(2-hydroxyphenyl)methylideneamino]ethyliminomethyl]phenol;iron(2+)
- DTXSID50743076
- 14167-12-5
- N,N/'-DISALICYLAL-ETHYLENEDIAMINE IRON(II)
- N,N-DISALICYLAL-ETHYLENEDIAMINEIRON(II)
- AKOS015833245
- iron(2+);6-[[2-[(6-oxocyclohexa-2,4-dien-1-ylidene)methylamino]ethylamino]methylidene]cyclohexa-2,4-dien-1-one
- AAJGISIJWYVWOG-UHFFFAOYSA-N
-
- MDL: MFCD01631307
- Inchi: 1S/C16H16N2O2.Fe/c19-15-7-3-1-5-13(15)11-17-9-10-18-12-14-6-2-4-8-16(14)20;/h1-8,11-12,19-20H,9-10H2;/q;+2/b17-11+,18-12+;
- InChI Key: AAJGISIJWYVWOG-OYJDLGDISA-N
- SMILES: [Fe+2].OC1C=CC=CC=1/C=N/CC/N=C/C1C=CC=CC=1O
Computed Properties
- Exact Mass: 322.04000
- Monoisotopic Mass: 324.056113g/mol
- Isotope Atom Count: 0
- Hydrogen Bond Donor Count: 0
- Hydrogen Bond Acceptor Count: 4
- Heavy Atom Count: 21
- Rotatable Bond Count: 5
- Complexity: 298
- Covalently-Bonded Unit Count: 2
- Defined Atom Stereocenter Count: 0
- Undefined Atom Stereocenter Count : 0
- Defined Bond Stereocenter Count: 0
- Undefined Bond Stereocenter Count: 0
- Topological Polar Surface Area: 65.2?2
Experimental Properties
- Color/Form: Not determined
- PSA: 43.18000
- LogP: 1.77950
- Solubility: Not determined
Iron,[[2,2'-[1,2-ethanediylbis[(nitrilo-kN)methylidyne]]bis[phenolato-kO]](2-)]- Pricemore >>
| Related Categories | No. | Product Name | Cas No. | Purity | Specification | Price | update time | Inquiry |
|---|---|---|---|---|---|---|---|---|
| SHENG KE LU SI SHENG WU JI SHU | sc-295818-1g |
N,N′-Bis(salicylidene)ethylenediamine Iron(II), |
14167-12-5 | ≥90% | 1g |
¥2738.00 | 2023-09-05 | |
| SHENG KE LU SI SHENG WU JI SHU | sc-295818A-5g |
N,N′-Bis(salicylidene)ethylenediamine Iron(II), |
14167-12-5 | ≥90% | 5g |
¥8123.00 | 2023-09-05 | |
| SHENG KE LU SI SHENG WU JI SHU | sc-295818-1 g |
N,N′-Bis(salicylidene)ethylenediamine Iron(II), |
14167-12-5 | ≥90% | 1g |
¥2,738.00 | 2023-07-10 | |
| SHENG KE LU SI SHENG WU JI SHU | sc-295818A-5 g |
N,N′-Bis(salicylidene)ethylenediamine Iron(II), |
14167-12-5 | ≥90% | 5g |
¥8,123.00 | 2023-07-10 |
Iron,[[2,2'-[1,2-ethanediylbis[(nitrilo-kN)methylidyne]]bis[phenolato-kO]](2-)]- Related Literature
-
Vishwesh Venkatraman,Marco Foscato,Vidar R. Jensen,Bj?rn K?re Alsberg J. Mater. Chem. A, 2015,3, 9851-9860
-
Chung-Sung Yang,Mong-Shian Shih,Fang-Yi Chang New J. Chem., 2006,30, 729-735
-
Guiying Zhang,Maosheng Cheng,Yanni Li,Keliang Liu,Lifeng Cai Chem. Commun., 2013,49, 11086-11088
-
Sowmyalakshmi Venkataraman RSC Adv., 2015,5, 73807-73813
-
Manickam Bakthadoss,Tadiparthi Thirupathi Reddy,Vishal Agarwal,Duddu S. Sharada Chem. Commun., 2022,58, 1406-1409
Additional information on Iron,[[2,2'-[1,2-ethanediylbis[(nitrilo-kN)methylidyne]]bis[phenolato-kO]](2-)]-
Research Briefing on Iron,[[2,2'-[1,2-ethanediylbis[(nitrilo-kN)methylidyne]]bis[phenolato-kO]](2-)]- (CAS: 14167-12-5)
Iron,[[2,2'-[1,2-ethanediylbis[(nitrilo-kN)methylidyne]]bis[phenolato-kO]](2-)]-, with the CAS number 14167-12-5, is a Schiff base iron complex that has garnered significant attention in recent chemical and biomedical research. This compound belongs to a class of metal-organic coordination complexes known for their diverse applications in catalysis, material science, and therapeutic development. The unique structural features of this iron complex, including its tetradentate N2O2 ligand environment, contribute to its stability and reactivity, making it a promising candidate for various biomedical applications.
Recent studies have focused on elucidating the molecular properties and potential applications of this iron complex. Structural characterization through X-ray crystallography reveals a distorted octahedral geometry around the iron center, with the Schiff base ligand adopting a planar configuration. Spectroscopic analyses, including UV-Vis and M?ssbauer spectroscopy, confirm the +3 oxidation state of iron in this complex, which is crucial for understanding its redox behavior in biological systems. The compound demonstrates remarkable stability under physiological conditions, a property that enhances its potential for in vivo applications.
In the field of medicinal chemistry, research has explored the anticancer potential of this iron complex. In vitro studies using various cancer cell lines have demonstrated significant cytotoxic activity, with particular efficacy against breast and colon cancer cells. Mechanistic investigations suggest that the complex induces apoptosis through reactive oxygen species (ROS) generation and mitochondrial membrane potential disruption. Importantly, the compound shows selective toxicity towards cancer cells while exhibiting minimal effects on normal cells, indicating a promising therapeutic window.
Another emerging application area for this iron complex is in antimicrobial therapy. Recent microbiological assays have revealed potent activity against both Gram-positive and Gram-negative bacteria, including drug-resistant strains. The complex appears to disrupt bacterial cell membranes and interfere with essential metabolic pathways. Of particular note is its effectiveness against methicillin-resistant Staphylococcus aureus (MRSA), a major concern in hospital-acquired infections.
From a chemical biology perspective, researchers have investigated the catalytic properties of this iron complex in biomimetic oxidation reactions. The compound demonstrates efficient catalytic activity in the oxidation of various organic substrates, mimicking the function of certain metalloenzymes. These properties have potential applications in industrial biocatalysis and the development of novel synthetic methodologies for pharmaceutical production.
Recent advances in formulation development have addressed previous challenges with the solubility and bioavailability of this iron complex. Novel nanoparticle-based delivery systems have significantly improved the compound's pharmacokinetic profile, enhancing its potential for clinical translation. Pharmacodynamic studies in animal models have shown favorable tissue distribution patterns and acceptable safety profiles at therapeutic doses.
Future research directions for this compound include further optimization of its therapeutic index, detailed investigation of its mechanism of action at the molecular level, and exploration of combination therapies with existing anticancer or antimicrobial agents. The ongoing development of this iron complex exemplifies the growing importance of metal-based compounds in addressing current biomedical challenges and advancing therapeutic options.
14167-12-5 (Iron,[[2,2'-[1,2-ethanediylbis[(nitrilo-kN)methylidyne]]bis[phenolato-kO]](2-)]-) Related Products
- 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
- 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
- 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
- 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
- 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
- 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
- 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
- 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
- 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
- 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)